Combined inhibition of IGF-1R and the Src family non-receptor tyrosine kinases leads to an effective suppression of AKT1 and AKT2 activation and consequently to a decreased intratibial tumor growth of prostate cancer cells [143]. This evidence concerns the gene SRC and prostate cancer.